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Abstract 
Interleukin-34 (IL-34) is a pro-inflammatory cytokine implicated in rheumatoid arthritis 
(RA). The present study aimed to assess the IL-34 expression in response to two 
members of the TGF-β family, TGF-β1 and BMP-2, in synovial fibroblasts from RA 
patients. IL-34, TGF-β1 and BMP-2 productions were measured in patient synovial 
fluids by ELISA. IL-34 mRNA levels were quantified by qPCR in human synovial 
fibroblasts and murine mesenchymal stem cells (mMSCs). Pharmacological 
inhibitions were used to determine the involvement of ALK1 and ALK5 downstream 
TGF-β1 and BMP-2. IL-34, TGF-β1 and BMP-2 were expressed in synovial fluids 
from RA patients. We found a significant correlation between IL-34 and TGF-β1 
expressions. Levels of both IL-34 and TGF-β1 were thus correlated with the total 
leukocyte counts in the synovial fluids. TGF-β1 and BMP-2 decreased IL-34 
expression in the synovial fibroblasts or in mMSC in a dose- and time-dependent 
manner through respectively ALK5 and ALK1 pathways. In addition, TGF-β1 
antagonized TNFα-induced IL-34 gene expression. This work identifies TGF-β1 and 
BMP-2 as potent inhibitors of IL-34 expression in RA synovial fibroblasts. These 
cytokines, as upstream inhibitors of IL-34, may thus contribute to antagonize 
inflammation and bone erosions in RA. 
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Introduction 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by a chronic 
inflammation of the synovial tissue that leads to progressive joint destruction.1 
Among the cells located in the inflamed joint, synovial fibroblasts are crucial players 
driving inflammation and bone erosion.2 
IL-34,3 basically described as promoting monocyte proliferation and survival, 
and osteoclast differentiation,4 is expressed by synovial fibroblasts of RA patients. Its 
expression, correlated with inflammation, the number of leucocytes and the severity 
of the synovitis, is upregulated by TNFα and IL-1β.5 
TGF-βs and BMPs, are proteins involved in control of many biological 
processes such as cell proliferation and differentiation. The importance of TGF-β for 
the pathogenesis of arthritis is emphasized by several observations made in patients 
and in animal models.6 TGF-β1 and its receptors TβRII were detected at high levels 
in the synovial fibroblasts of RA patients and in RA synovial fluids.7-9 In this context, 
numerous studies have demonstrated the beneficial effects of TGF-β in RA.6 TGF-β1 
suppresses acute and chronic arthritis in experimental models, and a strong increase 
of TGF-β1 expression was measured in the remission state of disease.10 Much less 
data exist regarding the role of BMP during the pathogenesis of RA. However, 
increasing evidences suggest that BMPs, known to play a crucial role in skeletal 
development, could play a major role in RA to restore function of synovial joints.11 In 
this study, we hypothesised that IL-34 expression could be modulated by TGF-β1 
and BMP-2. 
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Materials and Methods 
 
Synovial fluid  
Synovial fluids were obtained in the Rheumatologist Unit of Nantes University 
Hospital. The clinical characteristics of patients are summarized in Table 1. The 
study was approved by the local ethic committee and by the French Research 
Ministry (no 2008-402). IL-34, BMP-2 and TGF-β levels were measured in synovial 
fluids by ELISA assay (antibodies-online-GmbH for IL-34, R&D System for BMP-2 
and TGF-β1).  
 
Cell cultures 
Synovial fibroblasts, obtained from the synovial tissue of RA patients, and mouse 
C3H10T1/2 mesenchymal stem cells (MSCs), purchased from the ATCC (CCL-226), 
were cultured in alpha-MEM (Invitrogen) supplemented with 10% fetal bovine serum 
(Hyclone Perbio). TGF-β1 and BMP-2 were purchased from R&D System. ALK1 
inhibitor (LDN 212854) and ALK5 inhibitor (SB431542) were purchased from Sigma. 
 
Reverse transcription PCR analysis 
RNA was extracted using the NucleoSpin RNAII kit (Macherey-Nagel). One 
microgram of total RNA was used for first strand cDNA synthesis using 
ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA, USA). DNase I treatment 
(25 units, 15 min) of total RNA was performed to eliminate genomic contamination.. 
Real-time PCR was performed with a Chromo4 instrument (Biorad) using SYBR 
Green Supermix reagents (Biorad). Primer sequences were described in Table 2.  
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Western blot 
Western Blot analyses were performed as previously described.4 Briefly, cells were 
lysed in a lysis buffer (SDS 1%, Tris pH 7.4 10mM, Sodium orthovanadate 1 mM) 
and protein concentration was determined by BCA kit (Sigma). Twenty micrograms of 
total protein in Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 
2-mercaptoethanol, 0.001% bromophenol blue) were separated by SDS-
polyacrylamide gel electrophoresis, and transferred to Immobilon-P membranes 
(Millipore, Billerica, MA, USA). Membranes were immunoblotted with anti phospho-
Smad3 and Smad3 (Millipore), or phospho-Smad1/5 and Smad1/5 (Cell Signaling) 
antibodies. 
  
Confocal microcopy experiments 
Cell cultures, treated with TNF-α (10 ng/mL), and TGF-β1 (10 ng/mL) for 24h, were 
fixed and stained with the primary antibody against IL-34 (Diaclone, INSERM UMR 
957) as previously described.12 
 
Statistical analysis 
The Spearman test was use to look for a correlation between IL-34 expression and 
the diagnosis. Kruskal Wallis test was used to assess the change in gene 
expression. An alpha level of 0.05 was chosen to assess statistical significance. 
 
  6 
Results 
 
Increased production of IL-34 and TGF-β1 in RA synovial fluids 
The expression of IL-34, TGF-β1 and BMP-2 was detected in synovial fluids of RA 
patients (n=44, Figure 1A). IL-34 and TGF-β1 levels were associated with the 
inflammation intensity measured by the leukocyte counts (Figure 1B, respectively 
r=0.4, p=0.01 and r=0.36, p=0,02). A positive correlation between Il-34 and TGF-β 
levels in synovial fluids was found (Figure 1C, r=0.63, p<0.0001). No significant 
association was found between BMP-2 and IL-34 expression (Figure 1C), and 
between BMP-2 and the inflammation intensity measured by the leukocyte counts 
(Figure 1B). 
 
TGF-β1 and BMP-2 decrease Il-34 expression in human RA synovial fibroblasts and 
mMSCs 
The IL-34 mRNA steady-state levels following TGF-β1 or BMP-2 treatment were next 
investigated by quantitative RT-PCR. Both TGF-β1 (10 ng/ml) and BMP-2 (100 
ng/ml) significantly decreased IL-34 mRNA steady state levels in synovial fibroblasts 
from three different RA patients (Figure 2A, left panel) and in other mesenchymal 
cells such as mMSC (Figure 2A, right panel). The decrease of IL-34 expression in the 
presence of TGF-β1 or BMP-2 resulted in a time- and dose-dependent inhibition of 
IL-34 mRNA (Figure 2B and 2C). Only TGF-β1 down regulated M-CSF in human 
synovial cells (Figure 2D). 
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ALK5 and ALK1 receptors are involved in the inhibition of IL-34 expression driven by 
TGFβ1 or BMP-2 
Since BMP-2 and TGF-β1 preferentially signal from the membrane to the nucleus via 
respectively ALK1 and ALK5 receptors, we used validated chemical inhibitors of 
ALK1 (LDN 212854) and ALK5 (SB431542). We first demonstrated that BMP-2 and 
TGF-β1 stimulate respectively the ALK1/Smad1-5 and the ALK5/Smad2-3 signaling 
pathways (Figure 3A, left panels). We secondly demonstrated that LDN 212854 and 
SB431542 specifically inhibit the ALK1/Smad1-5 and the ALK5/Smad2-3 signaling 
pathways in mMSC (Figure 3A, middle and right panels). Then, we observed that 
ALK1 and ALK5 inhibitors block the response to respectively BMP-2 and TGF-β1 in 
mMSC (Figure 3B). Similarly, in fibroblasts of two RA patients (P1 and P2), we 
observed that the ALK5 inhibitor reverses the effect of TGF-β1 on IL-34 gene 
expression and that the ALK1 inhibitor partially reverses the effect of BMP-2 (Figures 
3C and 3D). Interestingly, TGF-β1 stimulates BMP-2 mRNA steady state level in RA 
synovial fibroblasts (Supplemental Figures S1). 
 
TGF-β1 inhibits IL-34 expression in inflammatory conditions 
Since pro-inflammatory cytokines such as IL-1β and TNF-α play a crucial role in RA 
and since we previously demonstrated that TNF-α induces IL-34 expression,5 we 
studied the effect of TGF-β1 and BMP-2 in inflammatory conditions. To this end, cells 
were treated with TNF-α. As shown in Figure 4, TGF-β1 (Figure 4A) and BMP-2 
(Figure 4B) significantly reduce the response of the cells to TNF-α. Specifically, TGF-
β1 and BMP-2 repress the basal levels of IL-34 rather than directly the response of 
the cells to TNF-α. Confocal microscopy analyses confirmed that IL-34 production 
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paralleled the modulation of IL-34 mRNA (Figure 4C). Specifically, TNF-α treatment 
resulted in an increase of IL-34 production in contrast to TGF-β1 which markedly 
reduced it. To ascertain this results on protein level, we quantified the IL-34 
production by ELISA approach. As shown in Figure 4D, ….. 
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Discussion 
 
Scientific studies have focused on the complex role of cytokines in the development 
and progression of RA. During the last decade, it has been demonstrated that pro-
inflammatory cytokines such as TNF-α or IL-1β play a crucial role in the 
pathophysiology of RA. These cytokines indeed promote inflammation and 
osteoclastogenesis in the arthritic joint leading to the destruction of cartilage and 
bone.13 In this context, neutralizing TNF-α has proven successful to control RA in 
many cases.13 During the last years, new pro-inflammatory cytokines, such as IL-32, 
IL-34 or IL-35  have been studied for their role in the pathogenesis RA. Recently, we 
demonstrated that IL-34, as a downstream effector of TNFα and IL-1β, is involved in 
the pathogenesis of RA.5  
A better understanding of the mechanisms regulating the expression of this 
cytokine should allow to development new therapeutic approaches. We identified 
here two cytokines, BMP-2 and TGF-β1 able to inhibit IL-34 gene expression. We 
specifically demonstrated that TGF-β1 and BMP-2 inhibit IL-34 expression in synovial 
fibroblasts and in mMSC via respectively the ALK1 and ALK5 receptors.  BMP-2 may 
indirectly reduce bone resorption by inhibiting the expression of IL-34 known to be 
able to stimulate osteoclastogenesis.4 BMP-2 could thus prevent the bone 
degradation in RA by directly stimulating bone formation and indirectly by inhibiting 
bone resorption. 
The role of TGF-β, identified  as a pro-fibrotic agent in many tissues,14 remains 
unclear in RA. It appears that this cytokine, involved in the pannus development,9 
could act as a pro-fibrotic agent in RA. In this context, some authors demonstrated 
the beneficial effects of TGF-β in RA.6 Indeed, systemic administration of TGF-β1 
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antagonized the development of polyarthritis in susceptible rats.15 In addition, the 
inhibition of TGF-β signaling increased the clinical severity of arthritis in collagen-
induced arthritis model.10  
To resume, we describe for the first time, the regulation of IL-34 expression by 
BMP-2 and TGF-β in the context of inflammatory stimulation. Such control loops 
appear to play a key role in the control of inflammation and bone resorption in RA 
(Figure 5). Future pre-clinical investigations are necessary to assess the potential 
clinical application of targeting IL-34 in RA. In addition, since BMP-2 and TGF-
 β1 have pleiotropic effects in different cells types, targeting these cytokines in RA 
need more investigations to define therapeutic treatments.  
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Figure legends 
 
Figure 1. IL-34, TGF-β1 and BMP-2 production in synovial fluid. 
Synovial fluid samples of RA patients were collected (n=44). A: Detection of IL-34, 
TGF-β1 and BMP-2 in synovial fluids. Each plot represents an individual sample. B: 
Correlation between levels of IL-34, TGF-β1, BMP-2 and total leukocyte count (mean 
+/-SD, each plot represents an individual sample). C: Correlation between levels of 
IL-34 and TGF-β, and of IL-34 and BMP-2. Each plot represents an individual 
sample. 
 
Figure 2. BMP-2 and TGF-β1 repress IL-34 mRNA expression. 
A: Synovial fibroblasts from three patients (left panel, P1 to P3) and mMSC (right 
panel) (means ± S.D., n=3, *p<0.05, ***p<0.001) were incubated in presence or 
absence of BMP-2 (100 ng/mL) or TGF-β1 (10 ng/mL) for 8h. IL-34 mRNA levels 
were determined by RT-qPCR.  
B: mMSC (means ± S.D., n=3, *p<0.05, ***p<0.001) were stimulated with BMP-2 (0, 
25, 50, 75, 100 or 200 ng/mL) for 8h (left panel), or with 100 ng/mL BMP-2 for either 
8, 24 or 48h (right panel). IL-34 mRNA levels were determined by qRT-PCR.  
C: mMSC (means ± S.D., n=3 *p<0.05, **p<0.01, ***p<0.001, ***p<0.001) were 
stimulated with TGF-β1 (0, 0.1, 1, 2.5, 5, or 10 ng/mL) for 8h (left panel), or with 10 
ng/mL TGF-β1 for either 8, 24 or 48h (right panel). IL-34 mRNA levels were 
determined by qRT-PCR.  
D: Synovial fibroblasts (P1 , P2 , P3) or mMSC (means ± S.D., n=3) were stimulated 
with BMP-2 (100 ng/mL) or TGF-β1 (10 ng/mL) for 8h. M-CSF mRNA levels were 
determined by qRT-PCR. 
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Figure 3. ALK5 and ALK1 receptors are involved in the inhibition of IL-34 
expression driven by TGFβ1 or BMP-2 
A: mMSC were incubated with SB431542 (10 µM) or LDN212854 (10 nM). 1h after, 
BMP-2 (100 ng/mL) or TGF-β1 (10 ng/mL) was added for 1h. Phospho-Smad levels 
were detected by Western Blot. Histogramms represent the ratio of the 
phosphoSmad to the total Smad protein levels.  
B: mMSC were incubated with SB431542 (10 µM) or LDN212854 (10 nM). 1h after, 
BMP-2 (100 ng/mL) or TGF-β1 (10 ng/mL) was added for 8h. Il-34 mRNA levels were 
determined by RT-qPCR. (means ± S.D., n=3, *p<0.05, ***p<0.001).  
C and D: synovial fibroblasts from two patient (P1 and P2) were incubated with 
SB431542 (10 µM, C) or LDN212854 (10 nM, D). 1h after, BMP-2 (100 ng/mL) or 
TGF-β1 (10 ng/mL) was added for 8h. Il-34 mRNA levels were determined by RT-
qPCR.  
 
Figure 4. TGF-β1 antagonizes TNF-α-induced IL-34. 
A and B: Synovial fibroblasts from three patients (P1 to P3) were stimulated with 
TNF-α (10 ng/mL) together with TGF-β1 (A, 10 ng/mL) or BMP-2 (B, 100 ng/mL) for 
8h. IL-34 mRNA levels were determined by RT-qPCR.  
C: Synovial fibroblasts cultured on labtek chamber slides were treated with TNFα (10 
ng/mL), TGF-β1 (10 ng/mL) or both for 24 h. IL-34 expression (pink), and nuclei 
stained by Hoechst reagent (blue) were observed by confocal microscopy. A 
representative experiment (X40) is shown. 
D: ELISA 
 
Figure 5. Schematic representation of the regulation of IL-34 expression in RA
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Table 1 : Characteristics of patients included in the study  
 
Leukocyte 
number/ 
mm3 
DMARS/ 
Biotherapy 
Corticosteroids Sex Age	(yrs)	
Duration	of	disease	
(months)	
Antibody status 
CRP(mg/l) 
ACPA RF 
High inflammatory fluids 
27000 Abatacept + F 59 360 + + ND 
22500 Tocilizumab + M 59 408 - + 45 
21000 
Tocilizumab/ 
MTX 
+ M 65 3 + + 217 
33600 Tocilizumab - M 53 132 + + <5 
30900 
 Tocilizumab/ 
MTX 
+ M 71 36 - - <5 
25320 Leflunomid + M 42 96 + - 39.8 
44100 MTX + M 40 10 - + 109 
48000 - + F 71 456 - ND ND 
43080 - - F 74 84 - - ND 
39900 - - M 77 36 + + 64 
38300 - - F 74 72 - - 23 
28000 - - F 81 120 + + 33 
22080 - + M 52 108 + + 59 
Moderate inflammatory Fluids 
14200 Abatacept + F 84 8 + + 95 
10710 Tocilizumab + F 66 216 + + 30 
19920 Rituximab + F 55 228 - + ND 
17000 
Adalimumab/ 
MTX 
+ M 53 144 ND + 62 
13000 MTX + F 66  ND  ND ND  ND 
11600 
MTX/Hydroxy
chloroquine 
+ F 64 1 + = 47 
Low inflammatory Fluids  
2280 
Abatacept/ 
MTX 
+ F 72 >200 + + 6 
9120 Tocilizumab + F 66 48 - - 31 
ND 
Tocilizumab/ 
MTX 
+ F 61 240 + + ND 
5600 Tocilizumab + F 44 108 - + 104 
2070 
Adalimumab/
MTX 
- F 43 192 + - 10 
6600 Adalimumab  + M 64 300 + + 7.9 
1700 
Adalimumab/
MTX 
+ M 51 132 + + <3 
1080 
Infliximab/ 
MTX 
ND M 60 96 + + ND 
5280 
Infliximab/ 
MTX 
- M 50 160 + + 4 
3600 
Infliximab/ 
MTX 
+ F 51 84 + + 58 
ND MTX + F 73 204 + + ND 
ND MTX - M 48 36 + + 15 
7440 MTX + F 52 20 + - ND 
7420 MTX  + F 83 36 + + 24.7 
4500 MTX + F 37 ND - - ND 
3500 MTX  + F 76  ND ND + ND  
9000 - + F 48 144 + + ND 
1200 - - F 68 140 - - 29.8 
4800 - + F 73 9 + + 30 
1380 - + F 45 120 + + 182 
2640 - + F 45 120 + + 182 
1500 ND ND F 55 ND ND ND ND 
4590 - - M 71 4 - - 87.7 
9120 - - M 46 1 + + 35 
ND ND ND F 59 ND ND ND ND 
 
MTX: Methotrexate; RF: Rheumatod Factor, ACPA: Anti-citrullinated Protein Antibody 
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Table 2: Sequences of primers  
 
human IL34 sens 5'-CTTACGAGGGGGTGTTCAGA-3' 
human IL34 antisens 5'-ACCAAGACCCACAGATACCG-3' 
mouse IL34 sens 5'-GGACACACTTCTGGGGACA-3' 
mouse IL34 antisens  5'-CCAAAGCCACGTCAAGTAGG-3' 
human GAPDH sens  5'-TGGGTGTGAACCATGAGAAGTATG-3' 
human GAPDH antisens 5'-GGTGCAGGAGGCATTGCT-3' 
mouse Hprt sens  5'-TCCTCCTCAGACCGCTTTT-3' 
mouse Hprt antisens   5'-CCTGGTTCATCATCGCTAATC-3' 
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Supplemental Figures 1. BMP-2 and TGF-β1 effect on TGF-B1 and BMP-2 
mRNA expression 
RA synovial fibroblast were incubated with BMP-2 (100 ng/mL) or TGF-β1 (10 ng/mL) 
for 8h. TGF-β1 (left panel) or BMP-2 (right panel) mRNA levels were determined by 
qRT-PCR.  
 
